Caught in the crossfire: p53 in inflammation

Carcinogenesis

Volumn 35, Issue 8, 2014, Pages 1680-1690

  Cooks, Tomer ^a   Harris, Curtis C ^a   Oren, Moshe ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Chronic inflammation; NF kB, mutant p53; p53 family members; p53 isoforms

Indexed keywords

CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE 2; MICRORNA 125B; MICRORNA 155; MICRORNA 21; PROTEIN P53; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ARTICLE; CARCINOGENESIS; CELL COMMUNICATION; CELL DEATH; CHRONIC INFLAMMATION; DNA DAMAGE; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; HUMAN; IMMUNOREGULATION; IMMUNOSURVEILLANCE; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; STRESS;

EID: 84905717306     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu134     Document Type: Article

References (162)

1. Levine, A. J. et al. (2009). The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9(10): 749-758.
2. Lane, D. et al. (2010). p53 Research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol 2(12): a000893.
3. Nigro, J. M. et al. (1989). Mutations in the p53 gene occur in diverse human tumour types. Nature 342(6250): 705-708.
4. Dittmer, D. et al.(1993). Gain of function mutations in p53. Nat Genet 4(1): 42-46.
5. Freed-Pastor, W. A. and C. Prives (2012). Mutant p53: one name, many proteins. Genes Dev 26(12): 1268-1286.
6. Bieging, K. T. et al. (2012). Deconstructing p53 transcriptional networks in tumor suppression. Trends Cell Biol 22(2): 97-106.
7. Sullivan, K. D. et al. (2012). The p53 circuit board. Biochim Biophys Acta 1825(2): 229-244.
8. Maltzman, W. and L. Czyzyk (1984). UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 4(9): 1689-1694.
9. Kastan, M. B. et al. (1992). A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71(4): 587-597.
10. Yonish-Rouach, E. et al. (1991). Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352(6333): 345-347.
11. Serrano, M., et al. (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88(5): 593-602.
12. Wang, Y. et al. (1998). Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs. Oncogene 17(15): 1923-1930.
13. Carvajal, L. A. et al. (2013). Another fork in the road--life or death decisions by the tumour suppressor p53. EMBO Rep 14(5): 414-421.
14. Lane, D. P. (1992). Cancer. p53, guardian of the genome. Nature 358(6381): 15-16.
15. Vogelstein, B. et al. (2000). Surfing the p53 network. Nature 408(6810): 307-310.
16. Reinhardt, H. C. et al. (2012). The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet 28(3): 128-136.
17. Wade, M. et al. (2013). MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 13(2): 83-96.
18. Love, I.M. et al. (2012). It Takes 15 to Tango: Making Sense of the Many Ubiquitin Ligases of p53. Genes Cancer 3(3-4):249-63.
19. Taira, N. et al. (2012). Post-translational modifications of p53 tumor suppressor: determinants of its functional targets. Histol Histopathol 27(4): 437-443.
20. Vousden, K. H. et al. (2009). Blinded by the Light: The Growing Complexity of p53. Cell 137(3): 413-431.
21. Goldstein, I. et al. (2012). Regulation of lipid metabolism by p53 - fighting two villains with one sword. Trends Endocrinol Metab 23(11): 567-575.
22. Johnson, R. F. et al. (2012). Nuclear factor-kappaB, p53, and mitochondria: regulation of cellular metabolism and the Warburg effect. Trends Biochem Sci 37(8): 317-324.
23. Shen, L., et al. (2012). The fundamental role of the p53 pathway in tumor metabolism and its implication in tumor therapy. Clin Cancer Res 18(6): 1561-1567.
24. Liu, J. et al. (2013). Tumor suppressor p53 and its mutants in cancer metabolism. Cancer Lett.
25. Dioufa, N. et al. (2012). p53 antagonizes the unfolded protein response and inhibits ground glass hepatocyte development during endoplasmic reticulum stress. Exp Biol Med (Maywood) 237(10): 1173-1180.
26. Thomas, S. E. et al. (2013). p53 and translation attenuation regulate distinct cell cycle checkpoints during endoplasmic reticulum (ER) stress. J Biol Chem 288(11): 7606-7617.
27. Maiuri, M. C. et al. (2010). Autophagy regulation by p53. Curr Opin Cell Biol 22(2): 181-185.
28. Lorin, S. et al. (2013). Autophagy regulation and its role in cancer. Semin Cancer Biol.
29. Scherz-Shouval, R. et al. (2010). p53-dependent regulation of autophagy protein LC3 supports cancer cell survival under prolonged starvation. Proc Natl Acad Sci U S A 107(43): 18511-18516.
30. Molchadsky, A. et al.(2010). p53 is balancing development, differentiation and de-differentiation to assure cancer prevention. Carcinogenesis 31(9): 1501-1508.
31. Paskulin, D. et al. (2012). The TP53 fertility network. Genet Mol Biol 35(4 (suppl)): 939-946.
32. Kawamura, T. et al.(2009). Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 460(7259): 1140-1144.
33. Sengupta, S. et al. (2005). p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 6(1): 44-55.
34. Grivennikov, S. I. et al. (2010). Immunity, inflammation, and cancer. Cell 140(6): 883-899.
35. Ben-Neriah, Y. et al. (2011). Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 12(8): 715-723.
36. Kimbrell, D. A. et al. (2001). The evolution and genetics of innate immunity. Nat Rev Genet 2(4): 256-267.
37. Ingersoll, M. A. et al. (2011). Monocyte trafficking in acute and chronic inflammation. Trends Immunol 32(10): 470-477.
38. Alessandri, A. L. et al. (2013). Resolution of inflammation: Mechanisms and opportunity for drug development. Pharmacol Ther 139(2): 189-212.
39. Fox, L. et al. (2010). Natural killer T cells: innate lymphocytes positioned as a bridge between acute and chronic inflammation? Microbes Infect 12(14-15): 1125-1133.
40. Boffetta, P. et al.(2003). Contribution of environmental factors to cancer risk. Br Med Bull 68: 71-94.
41. Azer, S. A. (2013). Overview of molecular pathways in inflammatory bowel disease associated with colorectal cancer development. Eur J Gastroenterol Hepatol 25(3): 271-281.
42. Sonnenberg, A. et al. (2013). Helicobacter pylori is a risk factor for colonic neoplasms. Am J Gastroenterol 108(2): 208-215.
43. Sun, B. et al. (2013). Inflammation and liver tumorigenesis. Front Med 7(2): 242-254.
44. Hofseth, L. J. et al.(2003). Nitric oxide in cancer and chemoprevention. Free Radic Biol Med 34(8): 955-968.
45. Vendramini-Costa, D. B. et al. (2012). Molecular link mechanisms between inflammation and cancer. Curr Pharm Des 18(26): 3831-3852.
46. Shibutani, S. et al.(1991). Insertion of specific bases during DNA synthesis past the oxidationdamaged base 8-oxodG. Nature 349(6308): 431-434.
47. Bindra, R. S. et al. (2005). Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis. Mutat Res 569(1-2): 75-85.
48. Sparmann, A. et al. (2004). Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6(5): 447-458.
49. Soucek, L. et al. (2007). Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 13(10): 1211-1218.
50. Cardona, S. M. et al.(2013). The fine balance of chemokines during disease: trafficking, inflammation, and homeostasis. Methods Mol Biol 1013: 1-16.
51. Guerra, C. et al. (2011). Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 19(6): 728-739.
52. Daniluk, J. et al. (2012). An NF-kappaB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest 122(4): 1519-1528.
53. Fuseya, C. et al. (2012). Involvement of pelvic inflammation-related mismatch repair abnormalities and microsatellite instability in the malignant transformation of ovarian endometriosis. Hum Pathol 43(11): 1964-1972.
54. Fleisher, A. S. et al.(2000). Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res 60(17): 4864-4868.
55. Schulmann, K. et al.(2005). Molecular phenotype of inflammatory bowel disease-associated neoplasms with microsatellite instability. Gastroenterology 129(1): 74-85.
56. Burgers, W. A. et al.(2007). Viral oncoproteins target the DNA methyltransferases. Oncogene 26(11): 1650-1655.
57. Peng, D. F. et al. Hirohashi (2005). Increased DNA methyltransferase 1 (DNMT1) protein expression in precancerous conditions and ductal carcinomas of the pancreas. Cancer Sci 96(7): 403-408.
58. Eguchi, K. et al. (1997). DNA hypermethylation at the D17S5 locus in non-small cell lung cancers: its association with smoking history. Cancer Res 57(21): 4913-4915.
59. Mishra, A. et al. (2012). Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell 22(5): 645- 655.
60. De Craene, B. et al. (2013). Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13(2): 97-110.
61. Maeda, H. et al. (1996). TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol 156(1): 73-78.
62. Torroella-Kouri, M. et al.(2009). Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated. Cancer Res 69(11): 4800-4809.
63. Wislez, M., N. Fujimoto, J. G. Izzo, A. E. Hanna, D. D. Cody, R. R. Langley, H. Tang, M. D. Burdick, M. Sato, J. D. Minna, L. Mao, I. Wistuba, R. M. Strieter and J. M. Kurie (2006). "High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras." Cancer Res 66(8): 4198-4207.
64. Ancrile, B., K. H. Lim and C. M. Counter (2007). "Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis." Genes Dev 21(14): 1714-1719.
65. Candido, J. et al. (2013). Cancer-related inflammation. J Clin Immunol 33 Suppl 1: S79-84.
66. Meng, T. C. et al. (2002). Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell 9(2): 387-399.
67. Nowsheen, S. et al.(2009). Accumulation of oxidatively induced clustered DNA lesions in human tumor tissues. Mutat Res 674(1-2): 131-136.
68. Kawanishi, S. et al. (2006). Oxidative and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol Chem 387(4): 365-372.
69. Hiraku, Y. et al.(2010). The role of iNOS-mediated DNA damage in infection- and asbestosinduced carcinogenesis. Ann N Y Acad Sci 1203: 15-22.
70. Williams, C. S. et al.(2000). Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105(11): 1589-1594.
71. Gupta, G. P. et al. (2007). Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446(7137): 765-770.
72. Qualtrough, D. et al.(2007). Prostaglandin F(2alpha) stimulates motility and invasion in colorectal tumor cells. Int J Cancer 121(4): 734-740.
73. Lippitz, B. E. (2013). Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 14(6): e218-228.
74. Meulmeester, E. et al.(2011). The dynamic roles of TGF-beta in cancer. J Pathol 223(2): 205-218.
75. Schetter, A. J. et al.(2010). Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 31(1): 37-49.
76. Chen, C. Z. et al.(2013). Regulation of immune responses and tolerance: the microRNA perspective. Immunol Rev 253(1): 112-128.
77. Chen, Z. et al.(2013). The pivotal role of microRNA-155 in the control of cancer. J Cell Physiol.
78. Iliopoulos, D. et al. (2010). STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 39(4): 493-506.
79. Medina, P. P. et al. (2010). OncomiR addiction in an in vivo model of microRNA-21-induced pre- B-cell lymphoma. Nature 467(7311): 86-90.
80. Li, Q. et al. (2013). MiR-21/Smad 7 signaling determines TGF-beta1-induced CAF formation. Sci Rep 3: 2038.
81. Staib, F. et al.(2005). The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. Cancer Res 65(22): 10255- 10264.
82. Polyak, K. et al.(1997). A model for p53-induced apoptosis. Nature 389(6648): 300-305.
83. Tan, M. et al.(1999). Transcriptional activation of the human glutathione peroxidase promoter by p53. J Biol Chem 274(17): 12061-12066.
84. Budanov, A. V. et al. (2004). Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 304(5670): 596-600.
85. Yoon, K. A. et al. (2004). Identification of ALDH4 as a p53-inducible gene and its protective role in cellular stresses. J Hum Genet 49(3): 134-140.
86. Hofseth, L. J. et al.(2003). Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A 100(1): 143-148.
87. Forrester, K. et al.(1996). "Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53." Proc Natl Acad Sci U S A 93(6): 2442-2447.
88. Chazotte-Aubert, L. et al.(2000). Nitric oxide nitrates tyrosine residues of tumor-suppressor p53 protein in MCF-7 cells. Biochem Biophys Res Commun 267(2): 609-613.
89. Han, J.A. et al. (2002) P53-mediated induction of Cox-2 counteracts p53- or genotoxic stressinduced apoptosis. EMBO J. 21(21):5635-44.
90. Khajeniazi, S. et al.(2013). Changes in COX-2 and oxidative damage factors during differentiation of human mesenchymal stem cells to hepatocyte-like cells is associated with downregulation of p53 gene. Biol Chem.
91. Niki, T. et al. (2002). Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas. Am J Pathol 160(3): 1129-1141.
92. Hunten, S. et al. (2013). The p53/microRNA network in cancer: experimental and bioinformatics approaches. Adv Exp Med Biol 774: 77-101.
93. Kasinski, A. L. (2012). miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res 72(21): 5576-5587.
94. Rivas, C. et al.(2010). Dual Role of p53 in Innate Antiviral Immunity. Viruses 2(1): 298-313.
95. Tomso, D. J. et al. (2005). Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation. Proc Natl Acad Sci U S A 102(18): 6431-6436.
96. Menendez, D. et al. (2011). The Toll-like receptor gene family is integrated into human DNA damage and p53 networks. PLoS Genet 7(3): e1001360.
97. Madenspacher, J. H. et al (2013). p53 Integrates host defense and cell fate during bacterial pneumonia. J Exp Med 210(5): 891-904.
98. Yamanishi, Y. et al. (2002). Regulation of joint destruction and inflammation by p53 in collageninduced arthritis. Am J Pathol 160(1): 123-130.
99. Zheng, S. J. et al.(2005). Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function. Diabetes 54(5): 1423-1428.
100. Park, J. S. et al. (2013). p53 controls autoimmune arthritis via STAT-mediated regulation of the Th17 cell/Treg cell balance in mice. Arthritis Rheum 65(4): 949-959.
101. Gudkov, A. V. et al. (2011). Inflammation and p53: A Tale of Two Stresses. Genes Cancer 2(4): 503-516.
102. Campisi, J. (2013). Aging, cellular senescence, and cancer. Annu Rev Physiol 75: 685-705.
103. Menendez, D. et al. (2013). Interactions between the tumor suppressor p53 and immune responses. Curr Opin Oncol 25(1): 85-92.
104. Rufini, A. et al. (2013). Senescence and aging: the critical roles of p53. Oncogene 32(43): 5129-5143.
105. Pribluda, A. et al. (2013). A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism. Cancer Cell 24(2): 242-256.
106. Li, T. et al.(2012). Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149(6): 1269-1283.
107. Ak, P. et al. (2010). p53 and NF-kappaB: different strategies for responding to stress lead to a functional antagonism. FASEB J 24(10): 3643-3652.
108. Kawauchi, K. et al. (2008). p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol 10(5): 611-618.
109. Ikeda, A. et al. (2000). p300/CBP-dependent and -independent transcriptional interference between NF-kappaB RelA and p53. Biochem Biophys Res Commun 272(2): 375-379.
110. Xia, Y. et al. (2009). Phosphorylation of p53 by IkappaB kinase 2 promotes its degradation by beta-TrCP. Proc Natl Acad Sci U S A 106(8): 2629-2634.
111. Wadgaonkar, R. et al. (1999). CREB-binding protein is a nuclear integrator of nuclear factor-kappaB and p53 signaling. J Biol Chem. 274(4):1879-82.
112. Campbell, K. J. et al. (2004). Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol Cell 13(6): 853-865.
113. Janssens, S. et al.(2006). Signals from within: the DNA-damage-induced NF-kappaB response. Cell Death Differ 13(5): 773-784.
114. Strozyk, E. et al.(2006). Differential effects of NF-kappaB on apoptosis induced by DNAdamaging agents: the type of DNA damage determines the final outcome. Oncogene 25(47): 6239-6251.
115. Lassus, P. et al. (1996). Anti-apoptotic activity of low levels of wild-type p53. EMBO J 15(17): 4566-4573.
116. Janicke, R. U. et al. (2008). The dark side of a tumor suppressor: anti-apoptotic p53. Cell Death Differ 15(6): 959-976.
117. Ryan, K. M. et al. (2000). Role of NF-kappaB in p53-mediated programmed cell death. Nature 404(6780): 892-897.
118. Lin, Y. et al. (2000). Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis. Nat Genet 26(1): 122-127.
119. Perkins, N. D. (2007). Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8(1): 49-62.
120. Elkon, R. et al. (2005). Dissection of a DNA-damage-induced transcriptional network using a combination of microarrays, RNA interference and computational promoter analysis. Genome Biol 6(5): R43.
121. Chien, Y. et al. (2011). Control of the senescence-associated secretory phenotype by NFkappaB promotes senescence and enhances chemosensitivity. Genes Dev 25(20): 2125-2136.
122. Janssens, S. et al. (2005). PIDD mediates NF-kappaB activation in response to DNA damage. Cell 123(6): 1079-1092.
123. Frank, A. K. et al. (2011). The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation. Mol Cell Biol 31(6): 1201-1213.
124. Bourdon, J. C. et al. (2005). p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19(18): 2122-2137.
125. Surget, S. et al. (2013). Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. Onco Targets Ther 7: 57-68.
126. Marcel, V. et al. (2011). Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death Differ 18(12): 1815-1824.
127. Surget, S. et al. (2013). Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. Onco Targets Ther. 7:57-68
128. Slatter, T. et al. (2011). Hyperproliferation, cancer, and inflammation in mice expressing a Delta133p53-like isoform. Blood 117(19): 5166-5177.
129. Campbell, H. G. et al. (2012). Does Delta133p53 isoform trigger inflammation and autoimmunity? Cell Cycle 11(3): 446-450.
130. Wei, J. et al. (2012). Pathogenic bacterium Helicobacter pylori alters the expression profile of p53 protein isoforms and p53 response to cellular stresses. Proc Natl Acad Sci U S A 109(38): E2543-2550.
131. Allocati, N. et al. (2012). p63/p73 in the control of cell cycle and cell death. Exp Cell Res 318(11): 1285-1290.
132. Dotsch, V. et al.(2010). p63 and p73, the ancestors of p53. Cold Spring Harb Perspect Biol 2(9): a004887.
133. Yang, A. et al. (2000). p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404(6773): 99-103.
134. Sasaki, Y. et al. (2003). Identification of the interleukin 4 receptor alpha gene as a direct target for p73. Cancer Res 63(23): 8145-8152.
135. Zaika, E. et al. (2013). Proinflammatory cytokines and bile acids upregulate DeltaNp73 protein, an inhibitor of p53 and p73 tumor suppressors. PLoS One 8(5): e64306.
136. Chatterjee, A. et al. (2010). Regulation of p53 family member isoform DeltaNp63alpha by the nuclear factor-kappaB targeting kinase IkappaB kinase beta. Cancer Res 70(4): 1419-1429.
137. King, K. E. et al.(2008). The p53 homologue DeltaNp63alpha interacts with the nuclear factor-kappaB pathway to modulate epithelial cell growth. Cancer Res 68(13): 5122-5131.
138. Lu, H. et al. (2011). TNF-alpha promotes c-REL/DeltaNp63alpha interaction and TAp73 dissociation from key genes that mediate growth arrest and apoptosis in head and neck cancer. Cancer Res 71(21): 6867-6877.
139. Oren, M. et al. (2010). Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2(2): a001107.
140. Muller, P. A. et al. (2013). p53 mutations in cancer. Nat Cell Biol 15(1): 2-8.
141. Izzotti, A. et al. (2004). Gene expression in the lung of p53 mutant mice exposed to cigarette smoke. Cancer Res 64(23): 8566-8572.
142. Yeudall, W. A. et al. (2012). Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis 33(2): 442-451.
143. Scian, M. J. et al. (2005). Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol 25(22): 10097-10110.
144. Weisz, L. et al. (2007). Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res 67(6): 2396-2401.
145. Schneider, G. et al. (2010). Cross talk between stimulated NF-kappaB and the tumor suppressor p53. Oncogene 29(19): 2795-2806.
146. Cooks, T. et al.(2013). Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 23(5): 634-646.
147. Hussain, S. P. et al. (2000). Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 60(13): 3333- 3337.
148. Ullman, T. A. et al. (2011). Intestinal inflammation and cancer. Gastroenterology 140(6): 1807-1816.
149. Matsumoto, Y. et al. (2007). Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med 13(4): 470-476.
150. Shatz, M. et al. (2012). The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells. Cancer Res 72(16): 3948-3957.
151. Moskovits, N. et al. (2006). p53 Attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Res 66(22): 10671-10676.
152. Kiaris, H. et al. (2005). Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Res 65(5): 1627-1630.
153. Addadi, Y. et al.(2010). p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res 70(23): 9650-9658.
154. Nishizaki, M. et al. (1999). Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effect. Clin Cancer Res 5(5): 1015-1023.
155. Trimis, G. et al. (2008). Expression of p21waf1/Cip1 in stromal fibroblasts of primary breast tumors. Hum Mol Genet 17(22): 3596-3600.
156. Hill, R. et al. (2005). Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 123(6): 1001-1011.
157. Bar, J. et al. (2009). Cancer cells suppress p53 in adjacent fibroblasts. Oncogene 28(6): 933-936.
158. Trachootham, D. et al. (2013). Loss of p53 in stromal fibroblasts promotes epithelial cell invasion through redox-mediated ICAM1 signal. Free Radic Biol Med 58: 1-13.
159. Sutton, T. A. et al. (2013). p53 is renoprotective after ischemic kidney injury by reducing inflammation. J Am Soc Nephrol 24(1): 113-124.
160. Krizhanovsky, V. et al. (2008). Senescence of activated stellate cells limits liver fibrosis. Cell 134(4): 657-667.
161. Lujambio, A. et al. (2013). Non-cell-autonomous tumor suppression by p53. Cell 153(2): 449-460.
162. Yamanishi, Y. et al (2002). Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A 99(15): 10025-10030.